Read Our Latest Analysis on Gilead Sciences Gilead Sciences Trading Down 1.8 % NASDAQ GILD opened at $104.08 on Friday. The stock’s 50-day simple moving average is $93.87 and its two-hundred day ...

DZ Bank upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a buy rating in a research report sent to investors on Thursday morning, Marketbeat Ratings reports.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Gilead Sciences has taken a major step towards increasing global access to HIV prevention with the signing of royalty-free voluntary licensing agreements with six generic manufacturers ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

$ 104.70 0.62 0.60% ...

Carrier Global Corporation (NYSE: CARR), global leader in intelligent climate and energy solutions, today announced that its venture group, Carrier Ventures, is leading an investment and technolog ...